BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Oragenics Announces Closing of $3.3 Million Preferred Stock Private Placement and $3.4 Million Debt Conversion into Equity

  Oragenics today announced that it has completed a private placement of $3.3 million of Non-Voting Series B Convertible Preferred Stock with four existing shareholders who are accredited investors including an entity affiliated with a director of the Company. Concurrently with the Preferred Stock Financing

  November 9, 2017

   · 

  8 min read
• Business

  Charles River Laboratories Announces Third-Quarter 2017 Results From Continuing Operations

  Revenue from continuing operations was $464.2 million, an increase of 9.0% from $425.7 million in the third quarter of 2016.

  November 9, 2017

   · 

  27 min read
• Drug Development

  Lancet Neurology Publishes Results From CSL Behring Phase III Study of Hizentra to Treat Patients With Chronic Inflammatory Demyelinating Polyneuropathy

  The Hizentra PATH study is the largest controlled clinical study in patients with CIDP.

  November 9, 2017

   · 

  8 min read
• Drug Development

  Myovant Sciences Announces Positive Top-line Results From Takeda’s Phase III Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated With Uterine Fibroids

  Relugolix met the primary endpoint with 57.6% of women achieving marked improvement in pain symptoms compared to 3.1% of women receiving placebo.

  November 9, 2017

   · 

  10 min read
• Genetown

  Avedro Marks the First Anniversary of Availability of the Only FDA Approved Corneal Cross-Linking Treatment in The U.S.

  Avedro, today marked the one year anniversary of the U.S. commercial availability of Photrexa Viscous and Photrexa.

  November 9, 2017

   · 

  4 min read
• Biotech Beach

  BIOLASE Announces Commencement of Rights Offering

  Under the terms of the rights offering, the Company distributed to its shareholders as of 5:00 p.m., Eastern Time, on November 8, 2017, the record date, 0.346 subscription rights exercisable for each share of the Company’s common stock owned.

  November 9, 2017

   · 

  4 min read
• Policy

  Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid Dependence

  The goal of this review should be to establish a shared national understanding of the characteristics of these medicines and the scientific and medical evidence supporting their use.

  November 9, 2017

   · 

  4 min read
• Business

  PENTAX Medical Announces License Agreement With American Speech-Language-Hearing Association To Digitize Clinical Assessment Tool For Voice Disorders

  The agreement was announced during the ASHA Annual Convention.

  November 9, 2017

   · 

  3 min read
• Business

  Sectra Signs Agreement With Teleradiology Provider to Improve Post-operative Follow-up for Orthopaedic Customers

  Through this agreement, Sectra can now offer its orthopaedic customers access to the service Sectra Implant Movement Analysis.

  November 9, 2017

   · 

  4 min read
• Business

  Photonic BioSystems Announces Out-Licensing Program for Microbiological Sensing and Liquid Handling Technologies

  The technology was originally developed for Department of Defense field applications.

  November 9, 2017

   · 

  3 min read